global cell therapy company providing proprietary non-viral cell engineering technology for the next generation of cell-based therapies including gene editing and immuno-oncology. MaxCyte has a blue chip client base, 120+ issued licences, and potential $800m+ pre-commercial milestone potential from existing licenses. In addition, MaxCyte is seeking independent financing for CARMA (mRNA-based CAR platform) to establish it as a separate therapeutics company and allow MaxCyte to focus on its core cell-engineering business.
Healthcare/Medical Diagnostics & Research
US - South Atlantic
Phase l or ll, Pre-Clinical Stage
Cell Therapy, Gene editing, Gene Therapy
22 Firstfield Road
Gaithersburg, MD 20878
Top 10 Holders of MaxCyte, Inc.
Top 10 Holders of MaxCyte, Inc. TEMP
Ownership data is sourced through FactSet.
Stock Market Data
Market Data copyright © 2020 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by